Guardant Health, Inc. (GH) has a negative trailing P/E of -27.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 80.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.62%, forward earnings yield 1.25%. PEG 0.65 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 57/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -9.2 | 0.00 | 5.34 | 16.86 | - |
| 2017 | -27.4 | 0.41 | 7.38 | 45.69 | - |
| 2018 | -37.6 | 2.46 | 6.62 | 35.26 | - |
| 2019 | -93.6 | 3.74 | 8.87 | 33.02 | - |
| 2020 | -49.5 | -0.21 | 9.68 | 43.83 | - |
| 2021 | -25.0 | -0.50 | 15.71 | 27.12 | - |
| 2022 | -4.2 | -0.06 | 46.18 | 6.18 | - |
| 2023 | -6.3 | 0.19 | 19.09 | 5.37 | - |
| 2024 | -8.6 | 0.51 | -26.85 | 5.07 | - |
| 2025 | -30.8 | 4.56 | -128.95 | 13.04 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.65 | $25.25M | $-46.14M | -182.7% |
| 2017 | $-1.18 | $49.84M | $-83.22M | -167% |
| 2018 | $-2.80 | $90.64M | $-85.06M | -93.8% |
| 2019 | $-0.75 | $214.38M | $-67.85M | -31.7% |
| 2020 | $-2.53 | $286.73M | $-246.28M | -85.9% |
| 2021 | $-3.80 | $373.65M | $-384.77M | -103% |
| 2022 | $-6.41 | $449.54M | $-654.59M | -145.6% |
| 2023 | $-4.28 | $563.95M | $-479.45M | -85% |
| 2024 | $-3.56 | $739.02M | $-436.37M | -59% |
| 2025 | $-3.32 | $982.02M | $-416.28M | -42.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.95 | $-3.50 – $-2.74 | $1.27B | $1.26B – $1.34B | 12 |
| 2027 | $-1.93 | $-2.73 – $-0.87 | $1.63B | $1.6B – $1.72B | 12 |
| 2028 | $-0.13 | $-0.51 – $0.42 | $2.05B | $2.04B – $2.06B | 8 |
| 2029 | $1.04 | $1.01 – $1.11 | $2.48B | $2.43B – $2.62B | 6 |
| 2030 | $2.36 | $2.30 – $2.52 | $3.05B | $2.99B – $3.22B | 6 |
